---
figid: PMC11813773__fonc-15-1514872-g003
figtitle: Anticancer effects of SBAs in Hepatocellular Carcinoma (HCC) and Pancreatic
  Cancer
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11813773
filename: fonc-15-1514872-g003.jpg
figlink: /pmc/articles/PMC11813773/figure/F3/
number: F3
caption: 'Anticancer effects of SBAs in Hepatocellular Carcinoma (HCC) and Pancreatic
  Cancer. (A) Effects in HCC: TUDCA: mitigates apoptosis induced by ER stress. CDCA:
  significantly increases NDRG2 expression, inhibiting hepatoma cell proliferation.
  Phosphorylates TGF-β via the TGR5-cAMP-PKA axis, enhancing T regulatory production.
  Inhibits cell growth in a dose- and time-dependent manner by increasing the Bax/Bcl-2
  ratio and upregulating caspase-3. Disrupts the cell cycle, modulates Bax/Bcl-2 gene
  expression, and induces apoptosis. Transforms oxaliplatin-induced necrosis into
  apoptosis by inhibiting ROS generation and activating the p53-caspase 8 pathway.
  (B) Effects in Pancreatic Cancer: UDCA: reduces intracellular ROS, Prx2 levels,
  epithelial-mesenchymal transition (EMT), and stem cell formation. DCA and CA: cause
  cell cycle arrest at the G0/G1 phase, effectively inhibiting pancreatic cancer cell
  proliferation'
papertitle: Carcinogenic and anticancer activities of microbiota-derived secondary
  bile acids
reftext: Mobina Kouhzad, et al. Front Oncol. 2025;15(NA).
year: '2025'
doi: 10.3389/fonc.2025.1514872
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media SA
keywords: secondary bile acids | carcinogenic | anticancer | microbiota | bile acids
automl_pathway: 0.8735539
figid_alias: PMC11813773__F3
figtype: Figure
redirect_from: /figures/PMC11813773__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11813773__fonc-15-1514872-g003.html
  '@type': Dataset
  description: 'Anticancer effects of SBAs in Hepatocellular Carcinoma (HCC) and Pancreatic
    Cancer. (A) Effects in HCC: TUDCA: mitigates apoptosis induced by ER stress. CDCA:
    significantly increases NDRG2 expression, inhibiting hepatoma cell proliferation.
    Phosphorylates TGF-β via the TGR5-cAMP-PKA axis, enhancing T regulatory production.
    Inhibits cell growth in a dose- and time-dependent manner by increasing the Bax/Bcl-2
    ratio and upregulating caspase-3. Disrupts the cell cycle, modulates Bax/Bcl-2
    gene expression, and induces apoptosis. Transforms oxaliplatin-induced necrosis
    into apoptosis by inhibiting ROS generation and activating the p53-caspase 8 pathway.
    (B) Effects in Pancreatic Cancer: UDCA: reduces intracellular ROS, Prx2 levels,
    epithelial-mesenchymal transition (EMT), and stem cell formation. DCA and CA:
    cause cell cycle arrest at the G0/G1 phase, effectively inhibiting pancreatic
    cancer cell proliferation'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BAS
  - HLA-DQA2
  - EPHB2
  - MAPK1
  - MAPK3
  - BAX
  - TGFB1
  - TGFB2
  - TGFB3
  - TP53
  - TP63
  - TP73
  - NDRG2
  - STAT3
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - PRDX2
  - PRRX2
  - ITK
  - SLC22A3
  - TUDCA
  - BAS
  - CDCA
  - ROS
---
